The United States Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Torrent Pharmaceuticals’ Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat from March 13, 2023 to March 17, 2023. At the end of the inspection, the company has been issued a ‘Form 483’ with 1 observation, which is procedural in nature.
Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.